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Abstract
Background: Spectrophotometry (SPT) could represent a promising technique for the diagnosis of cutaneous
melanoma (CM) at earlier stages of the disease. Starting from our experience, we further assessed the role of SPT in
CM early detection.
Methods: During a health campaign for malignant melanoma at National Cancer Institute of Naples, we identified a
subset of 54 lesions to be addressed to surgical excision and histological examination. Before surgery, all patients
were investigated by clinical and epiluminescence microscopy (ELM) screenings; selected lesions underwent
spectrophotometer analysis. For SPT, we used a video spectrophotometer imaging system (Spectroshade® MHT S.p.
A., Verona, Italy).
Results: Among the 54 patients harbouring cutaneous pigmented lesions, we performed comparison between
results from the SPT screening and the histological diagnoses as well as evaluation of both sensitivity and
specificity in detecting CM using either SPT or conventional approaches. For all pigmented lesions, agreement
between histology and SPT classification was 57.4%. The sensitivity and specificity of SPT in detecting melanoma
were 66.6% and 76.2%, respectively.
Conclusions: Although SPT is still considered as a valuable diagnostic tool for CM, its low accuracy, sensitivity, and
specificity represent the main hamper for the introduction of such a methodology in clinical practice. Dermoscopy
remains the best diagnostic tool for the preoperative diagnosis of pigmented skin lesions.
Background
The incidence of melanoma in Europe has been steadily
increasing, more rapidly than for any other cancer, dur-
ing recent decades. Incidence of melanoma deeply varies
across Europe, with the highest incidence in Scandina-
vian countries.
Lifetime risk of developing melanoma within the
entire caucasian population is estimated to be 1:535
individuals. Incidence is higher in individuals with fair
skin who have been exposed to high levels of UV-B
radiation. Mortality due to metastatic melanoma has
increased rapidly in both males and females; such a dis-
ease accounts for only 4% of skin cancers, but for 79%
of skin-cancer related deaths. In particular, mortality
rates are higher in males than in females; mortality has
doubled in males over the past 25 years. Again, death
rates are higher in individuals with fair skin. From 2002
to 2006, the median age at death due to metastatic mel-
anoma of the skin was 68 years. Both incidence and
mortality rates are highest in Australia and New
Zealand. The 5-year survival rate for patients with
advanced melanoma is less than 10% [1-6].
In melanoma patients, survival is strongly related to
tumor thickness; earlier diagnosis and complete excision
of lesions may thus lead to a decline in mortality for
such a disease. The most effective tool in fighting malig-
nant melanoma is detecting the disease with a depth of
≤ 1 mm (Breslow thickness) and without ulceration,
which is associated with an excellent prognosis (95%
5-year survival rate), in comparison to detection of a
malignant melanoma with a depth of > 4 mm (40%
* Correspondence: paolo.ascierto@gmail.com
1National Cancer Institute, Naples, Italy
Full list of author information is available at the end of the article
Ascierto et al. BMC Dermatology 2010, 10:5
http://www.biomedcentral.com/1471-5945/10/5
© 2010 Ascierto et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.5-year survival rate), as reported by the American Joint
Committee on Cancer [7].
Diagnostic accuracy for pigmented skin lesions using
the naked eye has been estimated to be about 60% [8].
To improve the accuracy of melanoma diagnosis, a vari-
ety of diagnostic instruments has been developed: der-
moscopy, multispectral imaging, confocal laser
microscopy, ultrasonography, optical coherence tomo-
graphy, or magnetic resonance imaging [9].
From its introduction in 1990s, dermoscopy or epilu-
minescence microscopy (ELM), a non-invasive tool for
cutaneous screenings, has become the most popular
technique for early diagnosis of melanoma [10-33], also
reducing the excess of cases addressed to excision
biopsy [34]. However, ELM is an useful tool in expert
hands. As stated in a systematic review by Kittler and
colleagues, dermoscopy does improve the diagnostic
accuracy for melanoma in comparison with eye-based
inspection, when used by experienced examiners only
[35]. Recentely, a meta-analysis evaluating diagnostic
accuracy for melanoma confirmed that sensitivity was
much higher for dermoscopy (0.90; 95% confidence
interval [CI], 0.80-0.95) than for naked eye examination
alone (0.71; 95% CI, 0.59-0.82), with an estimated differ-
ence of about 0.18 (95% CI, 0.09-0.27; P = 0.002) [36].
Conversely, there was no statistical evidence of a signifi-
cant difference in specificity [dermoscopy 0.90 (95% CI,
0.57-0.98) versus naked eye examination 0.81 (95% CI
0.48-0.95); difference 0.09 (95% CI, 0.06-0.23, P = 0.18)]
[36]. In addition, a meta-analysis of 30 studies using
dermoscopy showed a sensitivity of 0.88 (95% CI, 0.87-
0.89) and a specificity of 0.86 (95% CI, 0.85-0.86) [37].
Since sensitivity and specificity of dermoscopy signifi-
cantly vary among different studies without reaching the
100% of validity, additional non-invasive techniques,
such as spectrophotometric intracutaneous analysis
(SIA) and spectrophotometry (SPT), have been intro-
duced to improve early diagnosis of melanoma.
The SIA technique (SIAscopy, as named by Moncrieff
et al. [38]), which was developed using the model of
light transport [39,40], is aimed at differentiating mela-
nomas from non-melanoma skin cancers, benign mela-
nocytic naevi and other pigmented lesions such as
seborrhoeic keratosis [38].
The spectrophotometry is a method that evaluate the
color of a lesion by measuring its reflectance as a func-
tion of the wavelength. A pioneer in this field was Mar-
shall [41] who described a comprehensive analysis of
pigmented lesions under both ultraviolet and infrared
radiations. In such a study, he stated that the infrared
photographs tends to discriminate the different types of
lesions, with melanoma showing a relatively high degree
of correlation with low infrared reflectance.
The SPT (Spectroshade, MHT Verona, Italy) system
allows to extract information regarding the skin micro-
architecture, like the distribution, position, and quantity
of blood, collagen and melanin throughout the epider-
midis and papillary dermis, converting data from
reflected near infrared radiation into in vivo histological
images of the lesion [38]. The SPT system provides
information including a series of 15 multispectral images
into the near infrared bandwidth. On this regard, per-
manence of the image into the infrared area of the spec-
trum has been demonstrated to represent a significant
indication of malignancy of the pigmented lesion under
examination. Seven parameters (mean reflectans, MR;
variegation, V; area, A; dark area ratio, DAR; dark island
reflectance, DA; dark distribution factor, DDF) are pro-
cessed automatically by software, describing the pigmen-
ted lesion features. Three spectral areas play a major
role in quantification of all these parameters: 584 nm,
where the highest contrast between lesion and the sur-
rounding skin is determined; 650-750 nm, where a pig-
mented lesion can be better discriminated since the
light adsorption due to melanine is much higher than
that due to blood; 750-950 nm, where the lesion color is
quantified in the near infrared, a spectral area invisible
to the clinician’s eye. After exposing the skin to visible
light and infrared radiation, the spectrophotometric sys-
tem converts the reflected radiations into in vivo histo-
logical images of the lesion by means of a sophisticated
computer algorithm. Such an image allow to extract
information regarding the microarchitecture of the cuta-
neous alteration under examination.
Starting from our experience in the use of both ELM
and SPT, we intend to define the role of spectophoto-
metric diagnosis in the early detection of cutaneous
melanoma.
Methods
In recent years, physicians of the Melanoma Cooperative
Group at the National Cancer Institute of Naples have
performed a considerable amount of visits for cutaneous
screening (about 10.000 visits per year). For the evalua-
tion of clinically-relevant pigmented lesions, epilumines-
cence microscopy (ELM) was carried out using a
Molemax II (Derma Instruments, Vienna) video-
dermatoscope.
According to the criteria provided by our group for
the treatment of cutaneous pigmented lesions [42], each
patient was interviewed in order to obtain a personal
profile (date of birthday, place of residence, type of
work, history of sun exposure and sun burning, familial
recurrence of skin lesions), before undergoing a clinical
total body skin examination. Cutaneous pigmented
lesions were classified according to the macroscopic
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teria occurred, individuals were addressed to ELM-based
dermoscopy, in order to generate a risk classification.
Such an evaluation was made by expert dermatologists
(at least 3 years of experience). Lesions were classified
as non-melanocytic lesions (such as angiokeratoma, ver-
rucous naevus, pigmented basal cell carcinoma, sebor-
rhoeic keratosis, angioma, keratoacantoma, solar
keratosis, etc.) or melanocytic lesions [such as com-
pound naevus, intradermal naevus, papillomatous com-
pound naevus, Spitz naevus, blue naevus (without
pigment network); junctional naevus, lentigo simplex,
pigmented spindle cell naevus of Reed, naevus spilus,
cockarde naevus, atypical naevus, malignant melanoma
(with pigment network)] (Table 1).
Melanocytic lesions were further classified as very low,
low, medium, high, and very high risk lesions [18].
Characterization and classification of each lesion were
based on the presence or absence of typical ELM fea-
tures (Table 2) [18]. According to our working formula-
tion [42], each category was further classified as A (not
clinically suspicious) or B (clinical suspicious), on the
basis of the clinical history of the lesion (a suspicious
history is defined when a lesion presents a modification
of its clinical parameters during the past 6 months).
Surgical excision was advised for high and very high
risk lesions. In type A of medium, low, and very low
risk lesions, surgery may be justified on the basis of cos-
metic and/or functional reasons (in absence of contrain-
dications for surgical excisions). Anyway, patients with
medium risk lesions entered a close follow-up program.
Surgery was always recommended for all type B lesions
[42]. In case of advise for surgery of a melanocytic
lesion, patients were invited to participate in our study;
a written informed consent was obtained before patient’s
enrollment into the study.
Fifty-four individuals with cutaneous pigmented
lesions, who were addressed to surgery after ELM
classification, were also evaluated by spectrophotometry
(SPT), using the SpectroShade system (MHT, Verona,
Italy). Comparisons between SPT and ELM results were
conducted in order to verify whether SPT may highlight,
through multispectral image analysis, new features of
pigmented lesions (content and distribution of the
adsorbing components of the skin, such as melanin and
haemoglobin), which might be useful to improve the
early diagnosis of melanoma. Table 3 summarizes the
characteristics of the SPT classes and presents the corre-
lation with the ELM risk classification.
The study was reviewed and approved by the Ethycal
Committee at the National Cancer Institute of Naples
(Italy).
Statistical methods
SPT sensitivity and specificity as well as positive and
negative predictive values were determined according to
a computer-assisted statistical analysis using the SPSS
software for Windows, 8.0 version (SPSS Inc., Chicago,
USA). Taking histology as standard, a lesion was consid-
ered true positive (TP) or true negative (TN) if results
from SPT or ELM and histology were consistent (in
other words, a concordance was achieved using such
Table 1 ELM-based classification of cutaneous lesions
and corresponding histology
CUTANEOUS
LESIONS
HISTOLOGICAL LESIONS
Non-melanocytic
lesions
angiokeratoma, verrucous nevus, pigmented
basal cell carcinoma, seborrhoeic keratosis,
angioma, keratoacantoma, solar keratosis, etc.
Melanocytic
lesions
(without pigment
network)
compound nevus, intradermal nevus,
papillomatous compound nevus, Spitz nevus,
blue nevus.
(with pigment
network)
junctional nevus, lentigo simplex, pigmented
spindle cell nevus (Reed nevus), nevus spilus,
cockarde nevus, atipycal nevus, melanoma.
Other lesions squamous carcinoma, trichoepithelioma, Becker’s
nevus, Ota’s nevus, Ito’s nevus, Halo nevus.
Table 2 ELM-based risk classification for cutaneous
pigmented lesions
MELANOCYTIC
LESIONS
ELM FEATURES
Type 1
(very high risk)
Lesion with a pigment network and any of the
classical ELM features specific for melanoma
(pseudopods, radial streaming, blue-gray veil,
atypical vessel, etc.)
Type 2
(high risk)
Lesion with a pigment network and subtle new
ELM features that may suggest melanoma but
often are also seen in atypical nevi.
Type 3
(medium risk)
Lesion with a pigment network carrying subtle
perturbations that can be detected in atypical
naevus as well as in melanocytic hyperplasia.
Type 4
(low risk)
Lesion with a benign appearing network.
Type 5
(very low risk)
Lesion with a benign appearing network and with
a globular pattern or another benign ELM pattern.
Table 3 SPT diagnostic classes and corresponding ELM
risk classes
SPT
CLASSES
PROBABILITY OF
MELANOMA
CORRESPONDING ELM RISK
CLASS
1 no melanoma Non Melanocytic and Type 5
2 doubtful melanoma
(< 25%)
Type 4
3 suspected melanoma
(< 75%)
Types 3 and 2
4 probable melanoma
(> 75%)
Type 1
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considered as false positive (FP) or false negative (FN) if
histology did not confirmed the classification of SPT/
ELM (in other words, SPT/ELM was positive but histol-
ogy was negative or SPT/ELM was negative but histol-
ogy was positive). Sensitivity was calculated as TP/TP
+FN; specificity was calculated as TN/TN+FP; positive
predictive value was calculated as TP/TP+FP; negative
predictive value was calculated as TN/TN+FN.
Results
In a period of one year, total-body skin examinations for
detection of early malignant melanoma were carried out
at National Cancer Institute of Naples; they allowed to
identify cutaneous pigmented lesions to be addressed to
surgical excision and histological examination in 54
patients [35 females and 19 males; median age, 41
(range, 19-73 years)]. Before surgery, lesions were evalu-
ated by both ELM and SPT approaches.
According to ELM criteria [42], all 54 cutaneous pig-
mented lesions were classified as melanocytic lesions;
according to the risk criteria (Table 3), they were classi-
fied as very low risk (N = 11; 20%), low risk (7; 13%),
medium risk (1; 2%), high risk (21; 39%), and very high
risk (14; 26%) lesions. The comparison between ELM-
based classifications and histological results among the
54 excised lesions gave an agreement of 100% for very
low risk lesions (6 papillomatosus compound naevus
and 5 intradermal naevus), 100% for low risk lesions
(7 junctional naevus or compound naevus), 100% for
medium risk lesion (1 lentigo simplex), 90.4% for high
risk lesions (19 atypical naevus and 2 Reed naevus), and
85.7% for very high risk lesions (12 melanoma and 2
atypical naevus). Overall, agreement between histology
and ELM diagnosis was 92.5% (Table 4).
Before surgery, the same 54 selected pigmented lesions
were evaluated by SpectroShade software, which automa-
tically classified them in four different classes: group 1,
non melanoma; group 2, doubtful melanoma (< 25%);
group 3, suspected melanoma (< 75%); group 4, probable
melanoma (> 75%). Since criteria for classification into
such groups appeared to be not particularly accurate, we
decided to modify such a classification and correlate it to
the ELM-based risk assessment of each specific cuta-
neous lesion. Therefore, we defined the following classes:
group 1, non melanocytic and very low risk lesions;
group 2, low risk lesions; group 3, medium and high risk
lesions; group 4, very high risk lesions (Table 3).
Again, the comparison between SPT classifications
and histological results among the 54 excised lesions
gave an agreement of 66.6% (3 lesions) in group 1, 100%
(5 lesions) in group 2, 57.1% (28 lesions) in group 3,
and 44.4% (18 lesions) in group 4 (Table 5). Among all
pigmented lesions, agreement between histology and
SPT diagnosis was low (57.4%) (Table 5). Consistently,
the agreement between ELM and SPT classifications
was also quite low (overall, 68.5%) (Table 6).
As summarized in Table 7, SPT-based classifications
and histological results were evaluated for both sensitiv-
ity and specificity of this method among the 54 excised
lesions. The sensitivity and specificity of SPT in detect-
ing melanoma (group 4) were 66.6% and 76.2%, respec-
tively; moreover, the positive and negative predict values
were 44.4% and 88.9%, respectively (Table 7). Since the
rate of SPT diagnoses was progressively higher as the
thickness of the lesions increased (Table 8), the sensitiv-
ity and specificity of this method in detecting high risk
lesions (atypical naevi and melanomas) remained lower
than expected.
Discussion
Classification of pigmented lesions is actually based on
both clinical evaluation, by naked-eye, and dermoscopy
of the skin features; however, diagnosis strongly depends
on the experience of physicians. At present, the ELM
methodology, even in the hands of experienced exami-
ners, does not have 100% sensitivity and specificity
(overall, 88% sensitivity and 86% specificity [37]). To
improve the early detection of melanoma, new diagnos-
tic tools providing an automated classification of pig-
mented skin lesions (in other words, new devices which
could be also used by non-expert physicians) have been
proposed. Among others, the SPT is considered as the
most promising method for such a purpose.
Table 4 Agreement between ELM diagnosis and histology
Type of lesion ELM Diagnosis Histological Diagnosis Positive/Negative Agreement %
Non-melanocytic lesions - -/- -
Melanocytic lesions 54 50/4 92.5
Very low risk 11 11/- 100
Low risk 7 7/- 100
Medium risk 1 1/- 100
High risk 21 19/2 90.4
Very high risk 14 12/2 85.7
TOTAL 54 50/4 92.5
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study was quite small, our findings seem to indicate that
the SPT may have a limited role into the early diagnosis
of melanoma (66.6% sensitivity; 76.2% specificity; 44.4%
positive predicitive value; 88.9% negative predictive
value). About sensitivity, one melanoma (0.8 mm bre-
slow thickness, with a large dermal regression) was clas-
sified in group 1 (very low risk) by SPT; the other three
melanomas (median breslow thickness, 0,4 mm; range
0,3-0,7 mm) were classified in group 2 by SPT. Similarly,
s p e c i f i c i t yw a sq u i t el o ws i n c eo n l y8o u to f1 8l e s i o n s ,
which have been classified in group 4 by SPT, were
really malignant after histological diagnosis (conse-
quently, the agreement with histology was also low).
Another important issue is the difficulty to perform
the SPT evaluation on palpable lesions such as papillo-
matous naevi. In fact, 6 of these latter lesions and 3 der-
mal naevi were diagnosed in group 3 by SPT; therefore,
this contributed to lower the agreement with the histol-
ogy also in such a group.
Considering previous studies using the SPT approach,
some difference was observed among the image acquisi-
tion systems of the various instruments. However, the
Spectroshade® (MHT, Verona, Italy), which was used for
screening in our series, and the SIAscope (Astron Clin-
ica, Cambridge, UK), which has been commonly used
worldwide, are quite similar; both spectrophotometers
are able to acquire images at wavelengths between 483-
950 nm (Spectroshade) [43] or 400-1000 (SIAscope)
[38] and both of them use computer algorithms to ana-
lyze quite similar parameters of the pigmented lesions.
Therefore, it is possible to compare our results with
those reported in literature, using these two spectropho-
tometric systems. Table 9 summarizes the results from
the main studies published in past years [38,44-50].. Far-
ina et al. (2000) [45] reported the first large study
(including 237 patients) describing a pretty good sensi-
tivity (80%) but a low specificity (46%). Better results
were reported by Elbaum et al. (2001) [47] in a series of
246 patients; in this case, the authors used the Mela-
Find® (Electro-Optical Sciences Inc., Irvington, New
York, USA), a multispectral digital dermoscope with a
function similar to the others spectrophotometers,
which was described to achieve a sensitivity of 100%
and a specificity of 85%. Analogously, high values of
sensitivity and specificity were presented by two others
studies (Moncrieff et al., 2002 [38]; Govindan et al.,
2007 [49]); however, Moncrieff and colleagues con-
cluded that the SIAscope did not add accuracy in mela-
noma diagnosis in comparison with the dermatologist’s
long experience.
Consistently with this latter indication, Haniffa et al.
(2007) [48] reported high values of sensitivity (87%) and
specificity (91%) for SPT among 860 lesions examined
using the SIAscope spectrophotometer; when the same
lesions were however evaluated by a dermatologist with
a dermatoscope and at least 3 years of experience, sensi-
tivity and specificity resulted to be even higher (94% and
91%, respectively). Since diagnostic accuracy of dermo-
scopy and SPT was similar, again authors suggested that
a spectrophotometer does not improve the diagnostic
ability of experienced dermatologists [48]. Finally, the
Table 5 Agreement between SPT diagnosis and histology
Groups SPT
Diagnosis
Histological Diagnosis Positive/
Negative
Agreement
%
Group
1
3 2/1 66.6
Group
2
5 5/0 100
Group
3
28 16/12 57.1
Group
4
18 8/10 44.4
TOTAL 54 31/23 57.4
Table 6 Agreement between SPT and ELM classifications
Groups SPT
Diagnosis
ELM Diagnosis Positive/
Negative
Agreement
%
Group 1 3 2/1 66.6
Group 2 5 5/0 100
Group 3 28 16/12 57.1
Group 4 18 14/4 77.7
TOTAL 54 37/17 68.5
Table 7 Sensitivity and specificity for SPT in group 4
lesions
Histology
positive
Histology
negative
SPT positive 8 10 Sensitivity = 66.6
SPT negative 4 32 Specificity = 76.2
Table 8 Breslow thickness of melanomas diagnosed in
the series of 54 cutaneous lesions
BRESLOW THICKNESS
CATEGORIES
N. OF
CASES
MEDIAN BRESLOW
THICKNESS
RANGE
< 1 mm 5 0.7 0.3-1.0
1 1.0 -
1.01 to 2 mm 5 1.45 1.2-2.0
5 1.45 1.2-2.0
2.01 to 4.0 mm 2 2.25 2.1-2.4
2 2.25 2.1-2.4
> 4.01 mm 0 0 0
TOTAL 12 1.3 0.3-2.4
The 8 cases diagnosed by SPT are indicated in italic.
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sensitivity but a 59% specificity for SPT (as in Farina et
al., 2000 [45]), further indicating that such an approach
may overestimate the proportion of possible malignant
lesions (high amount of false positives).
Although the SPT is still considered as a valuable diag-
nostic tool, the low specificity of such a methodology
(probably, due to the interference of seborrhoeic kera-
toses, which are not always recognized as benign lesions)
represents the main hamper for the introduction of such
a diagnostic tool into the clinical practice. No sebor-
rhoeic keratosis was instead present in our series; there-
fore, we may speculate that the difference in diagnostic
accuracy between ELM and SPT was due to additional
factors in our study. Probably, the automated software of
the SPT might use some parameters that do not discrimi-
nate the features of melanoma or overestimate the role of
others skin components (blood, melanin, and collagen in
the infrared band) as markers of malignancy. Finally, the
agreement between the two screening methods was unsa-
tisfactory (68.5%), and the high number of false positives
in group 3 and 4 makes the ELM evaluation as the best
technique to help clinicians in early diagnosis of cuta-
neous melanoma. Consistently, SPT should be utilized in
clinical trials only.
Conclusions
The spectrophotometry (SPT) allows to accurately
define the skin microarchitecture features. However,
the low accuracy of SPT for either thin melanocytic
lesions (particularly, those with regression) or palpable
lesions (such as papillomatous and dermal naevi)
clearly indicates that dermoscopy remains the best
diagnostic tool for the preoperative diagnosis of pig-
mented skin lesions.
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